Amicus Therapeutics, Inc. (NASDAQ:FOLD) SVP Daphne Quimi sold 8,750 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $15.00, for a total value of $131,250.00. Following the completion of the transaction, the senior vice president now owns 73,082 shares in the company, valued at approximately $1,096,230. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Daphne Quimi also recently made the following trade(s):
- On Thursday, March 1st, Daphne Quimi sold 8,149 shares of Amicus Therapeutics stock. The shares were sold at an average price of $14.06, for a total value of $114,574.94.
- On Tuesday, January 2nd, Daphne Quimi sold 8,000 shares of Amicus Therapeutics stock. The shares were sold at an average price of $14.72, for a total value of $117,760.00.
Shares of Amicus Therapeutics, Inc. (FOLD) traded up $0.13 during trading on Monday, reaching $15.04. The company had a trading volume of 1,148,408 shares, compared to its average volume of 3,820,000. The company has a market capitalization of $2,500.00, a price-to-earnings ratio of -17.90 and a beta of 1.59. Amicus Therapeutics, Inc. has a 1-year low of $6.41 and a 1-year high of $17.40. The company has a quick ratio of 5.53, a current ratio of 5.60 and a debt-to-equity ratio of 0.47.
Institutional investors have recently modified their holdings of the stock. Strs Ohio bought a new stake in Amicus Therapeutics during the third quarter worth $102,000. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics during the third quarter worth $154,000. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the third quarter worth $155,000. Neuberger Berman Group LLC bought a new stake in Amicus Therapeutics during the third quarter worth $196,000. Finally, Great West Life Assurance Co. Can lifted its holdings in Amicus Therapeutics by 40.2% during the third quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 4,145 shares during the period.
A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. Cowen restated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Finally, Leerink Swann raised their target price on Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $19.06.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.